3 completed, 1 active not recruiting, 1 withdrawn. 3 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
| Early Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Abu Dhabi Stem Cells Center: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients Anti-TNF, JAK inhibitor - Rheumatoid Arthritis | Phase 3 | Withdrawn | Abu Dhabi Stem Cells Center | 2023-03-01 | 2025-10-06 | |
| Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus ECP regular-intensity arm, ECP accelerated-intensity arm, T1DM standard of care - Type 1 Diabetes | Early Phase 1 | Active not recruiting | Abu Dhabi Stem Cells Center | 10 | 2022-09-05 | 2025-12-26 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Extracorporeal Photopheresis, MS standard of care - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Completed | Abu Dhabi Stem Cells Center | 15 | 2022-03-26 | 2026-05-07 |
| Safety and Tolerability of Autologous Non-hematopoietic Peripheral Blood Stem Cells Therapy in Healthy Adult Volunteers. Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC). - Healthy | Phase 1 | Completed | Abu Dhabi Stem Cells Center | 18 | 2020-05-12 | 2020-11-27 |
| Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC), COVID-19 standard care - Coronavirus Disease 2019 (COVID-19) | Phase 1 / Phase 2 | Completed | Abu Dhabi Stem Cells Center | 146 | 2020-04-04 | 2020-07-16 |
Arthritis, Rheumatoid (1) · COVID-19 (1) · Diabetes Mellitus, Type 1 (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Photopheresis (2) · Adalimumab (1) · Certolizumab Pegol (1) · Etanercept (1) · Janus Kinase Inhibitors (1) · Photochemotherapy (1) · Therapeutics (1) · baricitinib (1) · golimumab (1) · tofacitinib (1) · upadacitinib (1)
United Arab Emirates (5)
Yendry Ventura Carmenate, M.D. (2) · Gianina Statache, MD (1) · Rene A. Rivero Jimenez, PhD (1) · Yandy M Castillo-Aleman, MD (1)